SAN DIEGO, California, USA, June 2, 2026
Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), a potential best-in-class Bruton’s tyrosine kinase (BTK) inhibitor being developed for multiple immune-mediated kidney diseases. The agreement, valued at up to $1.14 billion, grants Travere exclusive development and commercialization rights outside China and select East and Southeast Asian markets, strengthening the company’s position in the rapidly evolving nephrology therapeutics sector. The transaction underscores growing industry interest in innovative therapies targeting rare kidney disorders, where significant unmet medical need continues to drive investment and partnership activity.
Strategic Expansion of Rare Kidney Disease Portfolio
Under the terms of the agreement, Everest Medicines will receive an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in development, regulatory, and commercial milestone payments across multiple indications. Travere will also pay tiered royalties on future sales. The company views civorebrutinib as a potential “pipeline-in-a-product” opportunity due to its applicability across several immune-mediated kidney diseases, including primary membranous nephropathy (PMN), focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD).
Travere’s leadership highlighted that the therapy aligns strategically with its mission to deliver innovative treatments for patients suffering from rare renal disorders, where treatment options remain limited and disease progression can ultimately lead to dialysis or kidney transplantation. The addition of civorebrutinib broadens Travere’s development portfolio while diversifying future revenue opportunities within nephrology.
Promising Clinical Data Support Development Plans
Advertisement
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to offer differentiated efficacy, safety, and patient convenience. BTK plays a critical role in B-cell signaling pathways involved in immune activation and autoantibody production, making it a compelling target in autoimmune kidney diseases. The therapy has already demonstrated encouraging proof-of-concept data in a Phase 1/2 clinical trial in primary membranous nephropathy, where patients experienced rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, along with high rates of immunologic and clinical remission.
Importantly, kidney function remained stable throughout 52 weeks of follow-up, and the treatment was generally well tolerated. These results have reinforced confidence in civorebrutinib’s potential to become a transformative therapy for immune-mediated kidney disorders and support plans for expanded clinical development across additional renal indications.
Global Collaboration Targets Future Growth Opportunities
The partnership combines Everest Medicines’ innovative drug discovery capabilities with Travere’s established expertise in rare kidney disease development and commercialization. Both companies believe civorebrutinib’s highly selective and reversible BTK inhibition mechanism may offer broad therapeutic utility beyond its initial target indications. Future development programs are expected to explore the therapy’s role in additional autoimmune kidney diseases where immune-mediated damage contributes to proteinuria and progressive renal dysfunction.
As competition intensifies in the nephrology market, the collaboration positions both organizations to capitalize on growing demand for targeted therapies that can alter disease progression and improve long-term patient outcomes. If successfully developed and approved, civorebrutinib could emerge as one of the most important new therapies in rare kidney disease treatment, potentially reshaping standards of care while creating substantial commercial value for both companies.
Source: Travere Therapeutics, Everest Medicines press release
